[HTML][HTML] Equivalence of BCR-ABL Transcript Levels< 1% According to the International Scale with Complete Cytogenetic Response in Chronic Phase CML Patients.
M Lauseker, B Hanfstein, C Haferlach, S Schnittger… - Blood, 2012 - Elsevier
Abstract Abstract 2495 Introduction: Response to therapy in patients with chronic myeloid
leukemia (CML) is monitored by both cytogenetic assessment of bone marrow metaphases …
leukemia (CML) is monitored by both cytogenetic assessment of bone marrow metaphases …
Lösemili hastalarda direkt kromozom analiz yöntemi ile sitogenetik incelemeler
Ü Egeli - 1990 - acikerisim.uludag.edu.tr
Bu çalışmada KML (Kronik Myeloid Lösemi), KLL (Kronik Lenfositik Lösemi), AML (Akut
Myelositik Lösemi) tanısı konmuş 11 lösemili ve 2 prelökozlu hastadan direkt kromozom …
Myelositik Lösemi) tanısı konmuş 11 lösemili ve 2 prelökozlu hastadan direkt kromozom …
Comparison of Cytogenetics and Interphase Fluorescence In Situ Hybridization in Newly Diagnosed Ph+ Chronic Myeloid Leukemia Patients Treated with Imatinib …
N Testoni, S Luatti, C Nicci, E Montanari, G Marzocchi… - 2005 - ashpublications.org
To asses cytogenetic pattern of early diagnosed chronic phase chronic myeloid leukemia
(CML) patients and to evaluate the role of either conventional (CC) and molecular …
(CML) patients and to evaluate the role of either conventional (CC) and molecular …
[引用][C] Short Communication Reliability Evaluation of Fluorescence In Situ Hybridization (FISH) and G-Banding on Bone Marrow and Peripheral Blood Cells in Chronic …
MD Chavoshi, A Esfahani, AAM Akbari
[PDF][PDF] Molecular Diagnosis of Chronic Myeloid Leukemia & Monitoring Response to Different Types of Treatment
AN Al-Thwaini, MA Abdul-Sahib… - Journal of Biotechnology …, 2011 - iasj.net
Abstract hronic myeloid leukemia (CML) is one of leukemia types which account for 15% to
20% of all leukemia cases. Patients are presented with splenomegaly, fever, anemia …
20% of all leukemia cases. Patients are presented with splenomegaly, fever, anemia …
[引用][C] Co-evolution of the treatment and molecular diagnosis of chronic myeloid leukemia
FP Imparato, CL Menezes, A Anelli, RM Oliveira…
Quantification of Major BCR-ABL1 Fusion Gene Transcripts for Monitoring Therapeutic Response to Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia; …
안선현 - repository.ajou.ac.kr
BACKGROUND: CML is in> 90% of cases characterized by the presence of the Philadelphia
chromosome (Ph) and the corresponding fusion gene, BCR-ABL1. For disease monitoring …
chromosome (Ph) and the corresponding fusion gene, BCR-ABL1. For disease monitoring …
Qualitative and Quantitative Evaluation of the BCR-ABL Fusion Gene in Chronic Myelogenous Leukemia by Flourescence In Situ Hybridization and Molecular …
S Ozemri Sag, T Yakut, O Gorukmez… - Genetic testing and …, 2015 - liebertpub.com
Aims: Fluorescence in situ hybridization (FISH) and quantitative real-time polymerase chain
reaction (QRT-PCR) were used to diagnose or screen for minimal residual disease (MRD) in …
reaction (QRT-PCR) were used to diagnose or screen for minimal residual disease (MRD) in …
Evaluation of Therapy Response in Iranian CML Patients Using Quantitative PCR According to ELN Guideline 2013
B Poopak, G Khosravipoor, F Sheikhsofla… - 2015 - sid.ir
Abstract CHRONIC MYELOGENOUS LEUKEMIA (CML) IS ONE OF THE MOST
WIDESPREAD MYELOPROLIFERATIVE DISORDERS. APPROXIMATELY 90% TO 95% OF …
WIDESPREAD MYELOPROLIFERATIVE DISORDERS. APPROXIMATELY 90% TO 95% OF …
Fluorescent in situ hybridization monitoring and effect of detected early responses in the outcome of patients with chronic phase chronic myeloid leukemia: a report …
C Bourlon, C Hernandez-Mata… - … Myeloma and Leukemia, 2016 - Elsevier
Introduction The cytogenetic hallmark of chronic myeloid leukemia (CML) is the Philadelphia
chromosome. Monitoring the response in patients receiving therapy is a standard of care …
chromosome. Monitoring the response in patients receiving therapy is a standard of care …